Click to Translate to English Click to Translate to French  Click to Translate to Spanish  Click to Translate to German  Click to Translate to Italian  Click to Translate to Japanese  Click to Translate to Chinese Simplified  Click to Translate to Korean  Click to Translate to Arabic  Click to Translate to Russian  Click to Translate to Portuguese  Click to Translate to Myanmar (Burmese)

Forum Home Forum Home > Main Forums > Latest News
  New Posts New Posts RSS Feed - Phase II trials have started for Modrna vaccine
  FAQ FAQ  Forum Search   Events   Register Register  Login Login

Online Discussion: Tracking new emerging diseases and the next pandemic since 2005; Coronavirus COVID-19 Pandemic Discussion Forum.

Phase II trials have started for Modrna vaccine

 Post Reply Post Reply
Hazelpad View Drop Down
Adviser Group
Adviser Group

Joined: September 09 2014
Location: scotland
Status: Offline
Points: 5645
Post Options Post Options   Thanks (0) Thanks(0)   Quote Hazelpad Quote  Post ReplyReply Direct Link To This Post Topic: Phase II trials have started for Modrna vaccine
    Posted: June 01 2020 at 6:55pm

This is Modrna vaccine entering Phase II  already..  I cant make my mind up about it.  It's very different approach to vaccine development.  Not like the other more conventional  ones.  Anyone any thoughts or  see any pitfalls.

Hz x

Back to Top
Technophobe View Drop Down
Assistant Admin
Assistant Admin

Joined: January 16 2014
Location: Scotland
Status: Offline
Points: 78625
Post Options Post Options   Thanks (0) Thanks(0)   Quote Technophobe Quote  Post ReplyReply Direct Link To This Post Posted: June 02 2020 at 1:30am

The only person REALLY convinced of it's brilliance is Fauchi.

I am VERY pro-vaccine, but this whole approach of using RNA as the target worries me.  Altogether too strange and novel!  

Our bodies use messenger RNA and should our systems get a bit of the spelling wrong for antibodies, who knows what chaos would ensue?  Let's just say I am not likely to sign up for phase 3.  

It might work.  It might be safe.  But I am cautious.

Back to Top
Pixie View Drop Down
Admin Group
Admin Group

Joined: June 05 2006
Location: United States
Status: Offline
Points: 16538
Post Options Post Options   Thanks (0) Thanks(0)   Quote Pixie Quote  Post ReplyReply Direct Link To This Post Posted: June 03 2020 at 10:50am

Two of biotech company Moderna’s top executives dumped millions in company stocks just as the value peaked by 30 percent on news of early success in clinical trials for a COVID-19 vaccine. But right before medical reviews suggested that the results weren’t as promising as had been hyped, the company’s chief financial officer and chief medical officer sold off $30 million in company shares through an automated system that reads futures on certain volatile stocks. CNN Business reports that Lorence Kim, Moderna’s CFO, exercised 241,000 options for $3 million on Monday and then quickly sold them for $19.8 million, creating a profit of $16.8 million. Tal Zaks, Moderna’s chief medical officer, spent $1.5 million to exercise options the next day and then immediately sold the shares for $9.77 million, making a hefty profit of $8.2 million. Moderna says that because the sales were executed under a so-called 10b5-1 plan established in advance, they are not suspect. Former Moderna director Moncef Slaoui recently left the company to lead the White House’s vaccine development effort

New York (CNN Business)Moderna set off a frenzy on Wall Street earlier this month when it announced positive, preliminary results from its coronavirus vaccine trial. As the hype grew, the young biotech company and its leading investor wasted no time capitalizing on the briefly surging stock price.

Even as critics accused Moderna of overhyping the results released on May 18, a series of transactions were executed before its share price fizzled over the next week. The timing of those deals, former SEC officials said, appear to be "highly problematic" and should be investigated for potential illegal market manipulation.

Just hours after revealing the promising vaccine results, Moderna (MRNA) sold 17.6 million shares to the public. That share sale, unveiled after the closing bell on May 18, was priced at $76; Moderna traded at just $48 as recently as May 6. The deal instantly raised $1.3 billion.

Two of Moderna's top executives also cashed in on the boom at their company, which had suddenly amassed a $29 billion market value despite the fact it has no marketed products.

Heavy hearts soared Monday with news that Moderna’s Covid-19 vaccine candidate — the frontrunner in the American market — seemed to be generating an immune response in Phase 1 trial subjects. The company’s stock valuation also surged, hitting $29 billion, an astonishing feat for a company that currently sells zero products.

But was there good reason for so much enthusiasm? Several vaccine experts asked by STAT concluded that, based on the information made available by the Cambridge, Mass.-based company, there’s really no way to know how impressive — or not — the vaccine may be.

While Moderna blitzed the media, it revealed very little information — and most of what it did disclose were words, not data. That’s important: If you ask scientists to read a journal article, they will scour data tables, not corporate statements. With science, numbers speak much louder than words.

Back to Top
 Post Reply Post Reply
  Share Topic   

Forum Jump Forum Permissions View Drop Down